# Alpha-Tocopherol: Insufficient Data to Complete Drug Repurposing Assessment

## One-Sentence Summary

Alpha-tocopherol, the primary bioactive form of vitamin E, is a fat-soluble antioxidant widely present in foods and supplements.
In this Evidence Pack, **the TxGNN model generated no novel indication predictions**, and there are no registration data in the Singapore market or safety data. The assessment workflow cannot be initiated due to missing core data; it is recommended to complete the data first and then re-execute.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None (no approved registration in Singapore market) |
| Predicted New Indication | None (TxGNN produced no predictions) |
| TxGNN Prediction Score | None |
| Evidence Level | Cannot be determined (no prediction data) |
| Singapore Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why Can't This Evaluation Proceed?

Alpha-tocopherol is the most biologically active isoform of vitamin E, functioning primarily as a lipophilic free radical scavenger that exerts antioxidant effects to protect cell membranes from peroxidative damage. According to existing pharmacological knowledge, its applications span research directions including vitamin E deficiency, neuroprotection, and cardiovascular support.

However, this Evidence Pack has three fundamental gaps:

1. **No TxGNN prediction results**: the `predicted_indications` array is empty, the core input for drug repurposing assessment does not exist, and subsequent mechanism-of-action correlation analysis, clinical trial matching, and literature evidence cannot be conducted.
2. **No Singapore market registration**: `total_licenses = 0`, unable to confirm approved indications or current therapeutic positioning, Quick Overview table has no original indications to populate.
3. **Complete lack of safety data**: warnings, contraindications, and drug interactions have no data, DG001 has been flagged as **Blocking** level, and per assessment workflow rules, the preliminary safety evaluation has not passed and should not proceed to indication recommendation stage.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
TxGNN generated no predicted candidate indications, and the safety data gap has been flagged as Blocking level; the existing information is insufficient to support any recommendation decision.

**To proceed, the following is needed:**

- **Confirm DrugBank ID mapping**: Query DrugBank to confirm the correct DrugBank ID for ALPHA-TOCOPHEROL, and ensure the drug node exists in the TxGNN knowledge graph
- **Re-run TxGNN prediction**: using the correct DrugBank ID, re-execute the prediction workflow to generate `predicted_indications` data
- **Obtain Singapore HSA registration data**: Query the HSA drug database ([https://eservice.hsa.gov.sg/](https://eservice.hsa.gov.sg/)) to confirm whether there are products registered under the ingredient names "tocopherol" or "vitamin E"
- **Supplement mechanism of action (MOA)**: Obtain detailed mechanism descriptions via DrugBank API (DG002, High priority)
- **Download package insert and extract safety data**: Obtain warnings and contraindications (DG001, Blocking priority); assessment workflow can proceed only after passing preliminary safety evaluation
